METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study aims to cut hormone therapy side effects in prostate cancer
Disease control Not yet recruitingThis study tests a personalized approach to hormone therapy for men with metastatic hormone-sensitive prostate cancer. The goal is to reduce treatment intensity for lower-risk patients to minimize side effects while still controlling the cancer. About 108 participants will receiv…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Not yet recruitingThis phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision radiation may boost hormone therapy for advanced prostate cancer
Disease control Not yet recruitingThis study tests whether adding precisely targeted radiation to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer. All participants first receive six months of darolutamide plus androgen deprivation therapy. Those whose cancer has not progressed…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could surgery after hormone therapy beat advanced prostate cancer?
Disease control Not yet recruitingThis study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC